The world’s leading liver cancer meeting

ILCA 2023
17th Annual Conference
7-9 September, 2023
Amsterdam, The Netherlands

ilcalive.org  #ILCA23
# Final Programme

17th annual conference, 7-9 September 2023

## TABLE OF CONTENT

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Welcome</td>
<td>3</td>
</tr>
<tr>
<td>ILCA Annual Conference 2023 Programme</td>
<td>4</td>
</tr>
<tr>
<td>• Thursday, 7 September 2023</td>
<td>4</td>
</tr>
<tr>
<td>• Friday, 8 September 2023</td>
<td>7</td>
</tr>
<tr>
<td>• Saturday, 9 September 2023</td>
<td>10</td>
</tr>
<tr>
<td>ILCA Annual Conference Programme Committee</td>
<td>13</td>
</tr>
<tr>
<td>ILCA HUB</td>
<td>14</td>
</tr>
<tr>
<td>Practicalities</td>
<td>15</td>
</tr>
<tr>
<td>Sponsors, Media and other Partners</td>
<td>16</td>
</tr>
<tr>
<td>ILCA Industry Partners 2023</td>
<td>17</td>
</tr>
<tr>
<td>About ILCA</td>
<td>18</td>
</tr>
<tr>
<td>Industry Symposia</td>
<td>19</td>
</tr>
</tbody>
</table>
Dear ILCA members, colleagues and friends,

it is my pleasure and honour to welcome you to Amsterdam and the 17th Annual Conference of ILCA - the International Liver Cancer Association.

Over the years, our annual conference has been renowned for bringing liver cancer specialists from across the world together to learn from each other and dive into the critical issues that all of us face in our daily work. With the support of ILCA’s unique multidisciplinary community, I am proud that our conference is the leading liver cancer meeting in the world.

Our 2023 conference will once again focus on sharing innovative developments and providing a comprehensive overview of state-of-the-art treatment of common conditions in liver cancer practice. In addition to our series of plenary lectures, cutting-edge symposia, interactive workshops and our highly regarded ILCA Tumor Board, we are also experimenting this year with a new concept which we’re calling ‘ILCA Shark Tank’ and it promises to be a lot of fun!

Ever year, we bring physicians, young investigators, and leaders in the field from over 10 specialities together. A key part to attending our conference is the networking, making new connections and the informal conversations. This is a true benefit of attending in-person so make sure that you take the time to engage during the breaks with your fellow attendees and with our supporting companies in the exhibition.

None of this would be possible without the fantastic work of the ILCA Programme Committee led by Augusto Villanueva MD, PhD, and the outstanding work from the many presenters and from the ILCA staff. This event is also made possible due to the support of our ILCA partners, exhibitors, and to all of our attendees who are joining us from all four corners of the world. No matter where you have come from and no matter your career level, race, nationality, geography, ethnicity, age — you can rest assured that you are welcome at ILCA.

It is truly an honour for me to serve as your President. ILCA is growing as does our influence. It is an exciting time and we are changing lives...one patient at a time.

Warm regards,

Jessica Zucman-Rossi
ILCA President

Jessica Zucman-Rossi, MD, PhD
ILCA President

Augusto Villanueva, MD, PhD
ILCA Executive Secretary
## Final Programme
17th annual conference, 7-9 September 2023

### DAY 1 | Thursday, 7th September 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:00 - 11:05 | **Opening Ceremony**  
ILCA President: Jessica Zucman-Rossi, MD, PhD (France) |
| 11:15 - 13:15 | **Bench to bedside symposium on NASH HCC**  
Location: Plenary room  
**Session introduction from chairs**  
Jeong Min Lee, MD (Korea)  
Anjana Pillai, MD (USA) |
| 11:15 - 11:20 | **NASH limits anti-tumour surveillance in immunotherapy-treated HCC**  
Mathias Heikenwälder, MD, PhD (Germany) |
| 11:20 - 11:35 | **How to overcome NASH limited efficacy of immunotherapy**  
Derek A. Mann, BSc, MS (UK) |
| 11:35 - 11:50 | **New molecular drivers of NASH-related HCC**  
Nathalie Wong, MD, PhD (Hong Kong) |
| 11:50 - 12:05 | **Immune Landscape of Steatohepatitis-Driven HCC: Insights from Single-Cell and Spatial Transcriptomics Analyses**  
Valerie Chew, MD, PhD (Singapore) |
| 12:05 - 12:20 | **What is the expected clinical impact?**  
Helen Reeves, MD, PhD (UK) |
| 12:20 - 12:35 | **Roundtable and Questions & Answers** |
| 13:15 - 14:00 | **LUNCH BREAK & ILCA HUB** - Location: Exhibition & Poster Area  
**ILCA HUB**  
13.30 – 14.00  
Join Helen Morement, founder and CEO of AMMF – The Cholangiocarcinoma Charity, and learn the work AMMF is doing in the UK and Europe on cholangiocarcinoma. |
| 14:00 - 14:30 | **Clinical State of the Art**  
Location: Plenary room  
Chair: Josep Maria Llovet, MD, PhD (Spain)  
**Future of surgery in hepatocellular carcinoma**  
Myron Schwartz, MD (USA) |
## General Session 1 - Molecular Pathogenesis, Cell Biology and Translational Research

4 oral presentations from accepted abstracts and 8 poster blast presentations.

**Chairs:** Jesper Andersen, PhD (Denmark), Monika Lewinska, PhD (Denmark)

### 14:35-14:45

**O-01** - Effects of Tenofovir Disoproxil Fumarate on viral DNA integrations, chromosomal translocations, and immune microenvironment with implications for liver carcinogenesis in patients with mild chronic hepatitis. **Abhishek Aggarwal (USA)**

### 14:45-14:55

**O-02** - Spatial transcriptomic/TCR analysis reveals spatially suppressed beta-catenin activity and enriched infiltration of abT, gdT, and B lymphocytes in humanised HCC PDX models treated with combination of RTK inhibitors. **Timothy Shuen (Singapore)**

### 14:55-15:05

**O-03** - Integrated sc-RNAseq and untargeted metabolomics profiling demonstrated enriched monocyte-derived immunosuppressive macrophages in tumours of GATA4-deficient HCC with perturbed fatty acid homeostasis. **Rebecca Ba (Singapore)**

### 15:05-15:15

**O-04** - Dynamic evolution of circulating tumor DNA in patients with hepatocellular carcinoma across tumor stages and treatments. **Claudia Campani (France)**

### 15:05-15:15

**Questions & Answers**

### 14:30 – 15:50

**Poster blast**

8 selected poster presenters will introduce their poster in «2 minutes pitch».

**P-01** - Multimodal and spatial analysis of tumour-immune microenvironment in steatohepatitis-driven hepatocellular carcinoma. **Aldo Prawira (Singapore)**

**P-02** - Inhibition of PARP-1 in KRAS-mutated intrahepatic cholangiocarcinoma exerts positive effects and is mediated by CHK1 kinase. **Darko Castven (Denmark)**

**P-11** - Application of PROSASH model confirms survival benefit in patients treated with atezolizumab and bevacizumab compared to sorafenib in real-world setting. **Tim Meyer (UK)**

**P-12** - Transcriptomic analysis reveals non-immune tumor microenvironment features associated with clinical benefit in patients with hepatocellular carcinoma treated with SIRT plus Nivolumab. **Enrique Conde-Gallastegi (Spain)**

**P-13** - Financial and Psychological Burden of HCC Surveillance in Patients with Cirrhosis. **Amit Singal (USA)**

**P-15** - VETC (vessel that encapsulate tumor cluster) evaluated in liver biopsy predicts anti-angiogenic benefit in advanced HCC. **Luca Di Tommaso (Italy)**

**P-16** - Integrative analysis of genomic and proteomic data of hepatocellular carcinoma reveals consensus subtypes associated with clinical outcomes and therapeutic targets. **Ju-Seog Lee (USA)**

**P-20** - Prospective study of surveillance non-contrast abbreviated MRI for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound. **Mathew Vithayathil (UK)**

### 15:50-16:00

**Questions & Answers**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 – 16:30</td>
<td><strong>Coffee Break &amp; Networking &amp; ILCA Hub</strong> - Location: Exhibition &amp; Poster area</td>
</tr>
</tbody>
</table>
| 16:30 - 16:35 | **ILCA HUB**
|             | Would you like to know about the Y-ILCA Committee? Join and meet the Y-ILCA Committee and discuss with them! |
| 16:30 - 17:30 | **HCC Surveillance: How to bring new options to patients?** |
| 16:30 - 16:35 | **Introduction from Chairs**
|             | Amit Singal, MD, MS (USA)
|             | So Yeon Kim, MD (USA) |
| 16:35 - 16:50 | **New technologies**
|             | Augusto Villanueva, MD, PhD (USA) |
| 16:50 - 17:05 | **Study design: What evidence do we need to incorporate a biomarker in clinical practice**
|             | Nathalie Ganne, MD, PhD (France) |
| 17:05 - 17:20 | **Early Disease Research Network: Regulatory hurdles and how to move forward new biomarkers**
|             | Sudhir Srivastava, MD, PhD (USA) |
| 17:20 - 17:30 | **Questions & Answers** |
| 17:30 - 18:30 | **Roche Industry Symposium**
|             | Location: Plenary room |
| 18:30 - 19:30 | **Meet the Experts - Young Investigator Club**
|             | Organisers: Y-ILCA Committee Join the session to and sit down and converse and discuss on a more one-to-one level with the experts in the liver cancer field while enjoying a refreshment. |
|             | **Session Experts:**
|             | · Tim Greten, MD (USA)
|             | · Ana Lleo (Italy)
|             | · Jean-Charles Nault, MD, PhD (France)
|             | · Amit Singal, MD (USA)
|             | · Xin Wei Wang, PhD (USA)
|             | · Jessica Zucman-Rossi, MD, PhD (France) |
| 19:30 - 20:45 | **Poster Tour & Welcome Reception**
<p>|             | Poster tour basic chairs: Valérie Vilgrain, MD (France), Valerie Chew, MD, PhD (Singapore) Poster tour clinical chairs: Lorenza Rimassa, MD (Italy), Stephen Chan, MD, PhD, FAHA (Hong Kong) |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:30</td>
<td><strong>EISAI Breakfast Industry Symposium (breakfast available from 08:00)</strong>&lt;br&gt;Location: Plenary room</td>
</tr>
</tbody>
</table>
| 09:30 - 10:30 | **Basic Symposium - Spatial Omics**<br>Location: Plenary room  
**Introduction from Chairs**
Chairs: Lorenza Rimassa, MD (Italy), Augusto Villanueva, MD, PhD (USA)  
**Spatial transcriptomic analysis on HCC samples - With or without immunotherapy treatment**
Irene Ng, MD, PhD (Hong Kong)  
**Spatial Proteogenomics of Hepatic/HCC landscape**
Xin Wei Wang, PhD (USA)  
**Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma**
Qiang Gao, MD, PhD (China)  
Questions & Answers |
| 10:30 - 11:00 | **Coffee Break & Networking & ILCA Hub** - Location: Exhibition & Poster area  
**ILCA HUB**  
Attend the Diversity Session: “Knowing more about cancer in different populations improves cancer care for all populations; Increasing Participant and Investigator Diversity in Liver Cancer Research.”
- Ashraf Omar, MD, MSc (Egypt)  
- Bolni Marius Nagalo, PhD, MSc (USA)  
Session sponsored by **Boston Scientific** |
| 11:00 - 11:30 | **ILCA Advocacy**  
**ILCA Advocacy: Multidisciplinarity in treating liver cancer. A 360° perspective**
Chair: Bruno Sangro, MD, PhD (Spain)  
**Round table discussion with:**
- Helen Morement (UK)  
- Gemma Iserte (Spain)  
- Manon Allaire, MD (France) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:30 - 12:00 | **Presidential Address and Awards Ceremony**  
Nelson Fausto Award and Junior Investigator Awards  
In this session the International Liver Cancer Association is going to recognize 4 individuals for their outstanding contributions to advancing liver cancer research, Junior Investigator Awards as well as recognize this year Nelson Fausto Award. |
| 12:00 - 13:00 | **General Session 2: Epidemiology, Staging and Prognosis**  
4 oral presentations from accepted abstracts  
Chairs: Laura Kulik, MD (USA), David Pinato, MD, PhD (UK)  
12:05-12:15  
12:15-12:25  
**O-06** - Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SILVER clinical trial. Federico Piñero (Argentina)  
12:25-12:35  
**O-07** - Hepatocellular Carcinoma in HIV-Infected Patients: Clinical Presentation and Outcomes. Massimo Iavarone (Italy)  
12:35-12:45  
**O-08** - The liver frailty index is an independent predictor of mortality in patients with advanced hepatocellular carcinoma undergoing systemic therapy: a multicentre, prospective observational study. Karen Waller (Australia)  
12:45-13:00  
**Questions & Answers** |
| 13:00 - 14:00 | **AstraZeneca Lunch Industry Symposium**  
Location: Plenary room |
| 14:00 - 15:00 | **ILCA Debates**  
Location: Plenary room  
Chairs: Tim Meyer, MD, PhD (UK), Ivan Borbath, MD, PhD (Belgium)  
14:05-14:25  
**Debate 1: Topic Basic/Translational: Treatment response biomarkers: liquid biopsy vs tissue biomarkers?**  
Tim Greten, MD (USA) and Valerie Chew, MD, PhD (Singapore)  
14:25-14:45  
**Debate 2: Topic Clinical: Which should be first option in HCC? Atezo/bev vs durva/treme**  
Richard Finn, MD (USA) and Katie Kelley, MD (USA) |
### General Session 3 - Surveillance and diagnosis
#### 4 oral presentations from ILCA AC 2023 accepted abstracts

Chairs: Valerie Paradis, MD, PhD (France), Marco Sanduzzi, MD (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-15:15</td>
<td><strong>0-09</strong> Validation of serum biomarker panels for early HCC detection: Results from a large prospective Latin American multicenter study. Andre Boonstra (Netherlands)</td>
</tr>
<tr>
<td>15:15-15:25</td>
<td><strong>0-10</strong> GAAD and GALAD Algorithmic Scores Demonstrate Equivalent Clinical Performance for Detection of Early Stage Hepatocellular Carcinoma (HCC) in Prospective Multicenter Biomarker Studies. Masatoshi Kudo (Japan)</td>
</tr>
<tr>
<td>15:25-15:35</td>
<td><strong>0-11</strong> Validating liquid biopsy test based on a methylated SEPT9 assay for diagnosing hepatocellular carcinoma. Issei Saeki (Japan)</td>
</tr>
<tr>
<td>15:35-15:45</td>
<td><strong>0-12</strong> Complementary Value of AFP to Ultrasound for HCC Surveillance in Patients with Cirrhosis. Darine Daher (USA)</td>
</tr>
</tbody>
</table>

### Questions & Answers

#### Coffee Break & Networking & ILCA Hub - Location: Exhibition & Poster area

Meet the ILCA AC2023 Awardees! ILCA recognises extraordinary achievements in liver cancer research across disciplines and supports the professional development of four junior investigators in training. The four award recipients – two clinical and two basic researchers will be pleased to meet our participants and discuss their research.

16:30 - 17:30

**Tumor Board**

Location: Plenary room

- Chairs: Amit Singal, MD (USA), Richard Finn, MD (USA)
- Experts: Anjana Pillai, MD (USA), David Pinato, MD, PhD (UK), Anja Lachenmayer, PD, Dr, (Switzerland), Edward Kim, MD, (USA)
- Tumor Board Case 1: Ju Dong Yang (USA)
- Tumor Board Case 2: Heloise Giudicelli (France)

17:30 - 18:30

**Bayer Industry Symposium**

Location: Plenary room

18:30 - 19:00

**ILCA Masterclass: Clinical trial design (treatment and/or biomarker)**

Chairs: David Pinato, MD, PhD (UK), Marco Sanduzzi, MD (Spain)

- **Clinical trial design (treatment and/or biomarker)**
  - Expert: Jordi Bruix, MD (Spain)

Secure your seat for the ILCA Masterclass. Designed to be a very engaging, small group learning setting, this session will be limited to 50 participants. Dedicated registration at [ILCA Masterclass](#)
# Final Programme

## 17th annual conference, 7-9 September 2023

## DAY 3 | Saturday, 9th September 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chairs/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:30</td>
<td><strong>Guerbet Industry Symposium</strong>&lt;br&gt;Location: Plenary room</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:30</td>
<td><strong>Cholangiocarcinoma Educational Symposium</strong>&lt;br&gt;Location: Plenary room</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 09:35</td>
<td><strong>Session chairs introduction</strong>&lt;br&gt;Chairs: Lorenza Rimassa, MD, Italy, Heinz-Jozef Klumpen, MD, PhD (The Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:35 - 09:50</td>
<td><strong>Single-cell profiling of iCCA</strong>&lt;br&gt;Ana Lleo (Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:50 - 10:05</td>
<td><strong>On blood-based surveillance</strong>&lt;br&gt;Jesper Andersen, MD, PhD (Denmark)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05 - 10:20</td>
<td><strong>New systemic therapy options for iCCA</strong>&lt;br&gt;Rachna Schroff, MD, MS (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td><strong>Questions &amp; Answers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td><strong>Coffee Break &amp; Networking &amp; ILCA Hub</strong>&lt;br&gt;Meet and discuss with the presenters of the ILCA AC 2023 tumor Board cases.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td><strong>Basic State of the Art</strong>&lt;br&gt;Location: Plenary room&lt;br&gt;Chair: Valerie Chew, MD (Singapore)</td>
<td></td>
<td><strong>Unraveling the Complexities of Immunotherapy in Hepatocellular Carcinoma: Insights from Basic Science Research</strong>&lt;br&gt;Tim Greten, MD (USA)</td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td><strong>General Session 4: Therapy &amp; Miscellaneous</strong>&lt;br&gt;4 oral presentations from ILCA AC 2023 accepted abstracts&lt;br&gt;Chairs: Chris Verslype, MD, PhD (Belgium), Ken Liu, PhD (Australia)</td>
<td></td>
<td><strong>0-13 - Predictors of response to neoadjuvant immunotherapy in resectable hepatocellular carcinoma: preliminary clinical and translational analyses from the PRIME-HCC study.</strong>&lt;br&gt;Antonio D’Alessio (UK)</td>
</tr>
</tbody>
</table>
11:30 - 12:30

11:55-12:05
0-15 - Efficacy and safety analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
Masatoshi Kudo (Japan)

12:05-12:15
0-16 - Targeted therapy adapted to tumor biology in patients with advanced hepatocellular carcinoma or hepatocholedochocarcinoma refractory to atezolizumab/bevacizumab.
Wendy Limousin (France)

12:15-12:30
Questions & answers

12:30 - 13:15

ILCA Radiology Session
Chairs: Valérie Vilgrain, MD (France), Masatoshi Kudo, MD, PhD (Japan)

12:40-12:50
New imaging techniques for hepatocellular carcinoma surveillance: abbreviated MRI and future directions
Bachir Taouli, MD (USA)

12:50-13:00
Functional imaging in HCC: predicting molecular alterations with PET
Sabine Colnot, PhD, HDR (France)

13:00-13:10
Radiogenomics and Radiomics in Liver Cancers for prediction of prognosis
Azusa Kitao, MD, PhD (Japan)

13:10 – 13:15
Questions & Answers

13:15 - 14:00
Lunch Break & ILCA Hub
Amsterdam Genius Quiz results and winner announcement!

14:00 - 15:00

Shark Tank: Young Investigator research competition
Chairs: Laura Kulik, MD (USA), Monika Lewinska, PhD (Denmark)

4 young investigator candidates will be selected to present a 5-minute elevator pitch style research proposal. Proposals can be clinical or translational in nature but should generally be achievable in a one-year period.

Judges:
- Lorenza Rimassa, MD (Italy)
- Amit Singal, MD (USA)
- Augusto Villanueva, MD, PhD (USA)

Young Investigators:
- Luca Grisetti (Italy)
- Whitney Do (USA)
- Long Pan (France)
- Jing Fang (France)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td><strong>ILCA/EASL - Joint Symposium: New frontiers for immunotherapy in hepatocellular carcinoma</strong>&lt;br&gt;Chairs: Stephen Chan, MD, PhD, FAHA (Hong Kong), Jean-Charles Nault, MD, PhD (France)</td>
</tr>
<tr>
<td>15:05 - 15:20</td>
<td><strong>Immunotherapy in the setting of liver transplantation for HCC</strong>&lt;br&gt;Maria Reig, MD, PhD (Spain)</td>
</tr>
<tr>
<td>15:20 - 15:35</td>
<td><strong>Unresectable to resectable HCC: Hype or reality</strong>&lt;br&gt;Hui-Chuan Sun, MD (China)</td>
</tr>
<tr>
<td>15:35 - 15:50</td>
<td><strong>Predictive biomarker for immunotherapy in HCC</strong>&lt;br&gt;Mark Yarchoan, MD (USA)</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td><strong>Questions &amp; Answers</strong></td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td><strong>Closing Address</strong>&lt;br&gt;ILCA President: Jessica Zucman-Rossi, MD, PhD (France)</td>
</tr>
<tr>
<td>16:15 - 17:15</td>
<td><strong>General Assembly</strong>&lt;br&gt;ILCA members only</td>
</tr>
</tbody>
</table>
A Big Thank You to the Members of ILCA AC2023 Programme Committee for taking time out of their busy schedules to plan, organise and oversee the scientific programme. Their work and energy are making a difference at this year conference.

Augusto Villanueva  
Programme Committee Chair  
USA

Valerie Chew  
Singapore

Monika Lewinska  
Denmark

Lorenza Rimassa  
Italy

Amit Singal  
USA

Jessica Zucman-Rossi  
France

EXHIBITION FLOORPLAN

ILCA* Hub

Food and Beverage

Sponsors Booths:
1. Eisai
2. Roche
3. Guerbet
4. Bayer
5. AstraZeneca

*International Liver Cancer Association
COME AND JOIN US AT THE ILCA HUB LOCATED AT THE EXHIBITION AREA.

We will be organising a series of interactive activities which will be a great ice breaker to start conversations between delegates, faculty, and sponsor representatives.

The focus of the Hub is on authentic engagement – it provides an open space to exchange outside the box thinking and novel ideas, to bring people together in new ways and to collaborate on the big topics of our industry.

**Thursday, 7th September 2023**

- **Lunch break at 13:30 – 14:00**
  Join Helen Morement, founder and CEO of AMMF – The Cholangiocarcinoma Charity, and learn the work AMMF is doing in the UK and Europe on cholangiocarcinoma.

- **Coffee Break at 16:00 – 16:30**
  Meet and discuss with the Y-ILCA Young Investigator Committee members

**Friday, 8th September 2023**

- **Coffee Break at 10:30 – 11:00**
  Join Ashraf Osman and Bolni Marius Nagalo for the Diversity Session: “Knowing more about cancer in different populations improves cancer care for all populations; Increasing Participant and Investigator Diversity in Liver Cancer Research.” Session sponsored by Boston Scientific

- **Coffee Break at 16:00 – 16:30**
  Meet the ILCA AC2023 Awardees! ILCA recognises extraordinary achievements in liver cancer research across disciplines and supports the professional development of four junior investigators in training. The four award recipients – two clinical and two basic researchers will be pleased to meet our participants and discuss their research.

**Saturday, 9th September 2023**

- **Coffee Break at 10:30 – 11:00**
  Meet and discuss with the presenters of the ILCA AC 2023 tumor Board cases.

- **Lunch break at 13:30 – 14:00**
  Amsterdam Genius Quiz results and winner announcement!
PRACTICALITIES

• Accreditation
The International Liver Cancer Association’s 17th Annual Conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 17 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she spent in the educational activity.

• Junior Investigator Awards
ILCA will recognise extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The awards will be given for novel and significant liver cancer research across the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or cancer patients treatment. The investigators who submit the best clinical oral and best poster presentations and the best basic-translational oral and best poster presentations will be honoured LIVE on Friday, 8th September at 11.30 CEST (Central European Summer Time)

• Official Language
The official language of the conference is English. Simultaneous translation will not be provided.

Information is also available at www.ilca-online.org
ILCA warmly thanks all its sponsors, supporters and partners for their involvement in ILCA AC 2023.

Conference Sponsors & Supporters

Principal Sponsors

Eisai
AstraZeneca

Conference Sponsors

Bayer
Guerrbet
Roche

Conference Supporters

Boston Scientific
Incyte

Associations & Media Partners

ALEH
ASCO
ASL
cancers
EJSO
EMJ
ESO
Hepatoma Research
HPS
International Liver Transplantation Society
Together for better liver cancer patient treatment and care.

Liver cancer incidence rates are rapidly increasing across the world. And, because it is rarely detectable early, when it is most treatable, any liver cancer is difficult to cure.

Our industry partnership programme for 2023 offers healthcare companies the platform from which to support ILCA’s mission and values through educational, scientific activities and events.

We offer a strategic forum for high-level dialogue between ILCA leadership and industry partners to discuss the key issues for the future of liver cancer treatment, as well as recognition of your year-round partnership support.
Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to liver cancer by connecting expertise from interrelated fields, research and treatment levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted exclusively to liver cancer across disciplines.

**Our Mission**
ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from all interrelated fields and countries and strives to welcome and incorporate individuals involved in all the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual members. ILCA actively partners with other professional associations involved in any aspect related to liver cancer research, with the objective to join efforts for the benefit of science.

**Joining Our Community**
We invite you to discover more about ILCA on [www.ilca-online.org](http://www.ilca-online.org), as well as to connect with our expanding group of interested physicians, scientists, and allied health professionals from various fields and from around the world.

Membership to ILCA not only provides you with exclusive benefits such as reduced registration rates to our Annual Conferences, exciting networking and educational opportunities and active involvement in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research and care.

**ILCA Governing Board**

<table>
<thead>
<tr>
<th>Executive Committee</th>
<th>Council</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Valerie Chew, Singapore</td>
</tr>
<tr>
<td>Jessica Zucman-Rossi, France</td>
<td>R. Kate Kelley, USA</td>
</tr>
<tr>
<td>Executive Secretary</td>
<td>Laura Kulik, USA</td>
</tr>
<tr>
<td>Augusto Villanueva, USA</td>
<td>Jeong Min Lee, Republic of Korea</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Amaia Lujambio, USA</td>
</tr>
<tr>
<td>Lorenza Rimassa, Italy</td>
<td>Valérie Paradis, France</td>
</tr>
<tr>
<td>President Elect</td>
<td>Gonzalo Sapisochin, Canada</td>
</tr>
<tr>
<td>Tim Meyer, UK</td>
<td>Amit Singal, USA</td>
</tr>
<tr>
<td>Head of External Relations</td>
<td></td>
</tr>
<tr>
<td>Stephen Chan, Hong Kong</td>
<td></td>
</tr>
</tbody>
</table>
### Final Programme

17th annual conference, 7-9 September 2023

**THURSDAY 7th SEPTEMBER, 17:30–18:30 CEST**

**Title:** Expanding the view: early detection and systemic treatment opportunities in HCC

<table>
<thead>
<tr>
<th>TIME (CEST)</th>
<th>TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30-17:35</td>
<td>Welcome and introduction Presentation</td>
<td>Pierce Chow, MBBS, MMed, PhD (Singapore)</td>
</tr>
<tr>
<td>17:35-17:45</td>
<td>HCC surveillance, early detection and importance for patient outcomes Presentation</td>
<td>Amit Singal, MD, MS (US)</td>
</tr>
<tr>
<td>17:45-18:05</td>
<td>Current HCC systemic treatment options: where do we stand in clinical practice today? Presentation</td>
<td>David Pinato, MD, PhD (UK)</td>
</tr>
<tr>
<td>18:05-18:25</td>
<td>Q&amp;A and panel discussion: navigating the patient journey Discussion</td>
<td>All faculty</td>
</tr>
<tr>
<td>18:25-18:30</td>
<td>Summary and close Presentation</td>
<td>Pierce Chow, MBBS, MMed, PhD (Singapore)</td>
</tr>
</tbody>
</table>
## FRIDAY, 8 SEPTEMBER 2023, 08:30 – 09:30 CEST
EISAI Breakfast Industry Symposium

<table>
<thead>
<tr>
<th>TIME (CEST)</th>
<th>TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-08.35</td>
<td>Welcome and introduction</td>
<td>Professor Stephen Lam Chan</td>
</tr>
<tr>
<td>08.35-08.50</td>
<td>The changing HCC landscape</td>
<td>Professor Stephen Lam Chan and Professor Richard Finn</td>
</tr>
<tr>
<td>08.50-09.05</td>
<td>Child–Pugh B: an area of unmet need</td>
<td>Professor Stephen Lam Chan</td>
</tr>
<tr>
<td>09.05-09.20</td>
<td>Does real-world evidence suggest a role for aetiology in decision making?</td>
<td>Dr Andrea Casadei-Gardini</td>
</tr>
<tr>
<td>09.20-09.30</td>
<td>Q&amp;A discussion</td>
<td>All faculty and audience participation Facilitated by Professor Stephen Lam Chan</td>
</tr>
</tbody>
</table>
FRIDAY 8 SEPTEMBER 2023; 13:00–14:00 CEST
Title: Considerations for HCC patient care: MDT perspectives in the evolving era of immunotherapy

<table>
<thead>
<tr>
<th>TIME (CEST)</th>
<th>TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:05</td>
<td>Welcome and introduction Presentation</td>
<td>Laura Kulik, US</td>
</tr>
<tr>
<td>13:05-13:30</td>
<td>Tailoring treatment approaches to meet patient goals in unresectable HCC Presentation</td>
<td>Amit Singal, US Audience participation</td>
</tr>
<tr>
<td>13:30-13:40</td>
<td>Exploring the rationale for immunotherapy approaches in earlier stages of HCC Presentation</td>
<td>David Pinato, UK</td>
</tr>
<tr>
<td>13:55-14:00</td>
<td>Audience Q&amp;A</td>
<td>Laura Kulik, US Audience participation</td>
</tr>
</tbody>
</table>
**FRIDAY, 8 SEPTEMBER 2023, 17:30–18:30 CEST**

**Title:** Bridging the Gap: Integrating Specialties for Optimal Focal Liver Lesions Diagnosis and Management

<table>
<thead>
<tr>
<th>TIME (CEST)</th>
<th>TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30-17:35</td>
<td>Welcome and introduction</td>
<td>Prof. Amit Singal (Chair)</td>
</tr>
<tr>
<td>17:35-17:45</td>
<td>Importance of Early HCC Detection: Current Recommendations</td>
<td>Prof. Amit Singal</td>
</tr>
<tr>
<td>17:45-18:05</td>
<td>Decoding Focal Liver Lesions: Challenges and Advancements</td>
<td>Prof. Giuseppe Brancatelli</td>
</tr>
<tr>
<td>18:05-18:25</td>
<td>Current Treatment Landscape for HCC</td>
<td>Prof. Richard Finn</td>
</tr>
<tr>
<td>18:25-18:30</td>
<td>Discussion and Q&amp;A</td>
<td>All faculty</td>
</tr>
<tr>
<td>18:25-18:30</td>
<td>Closing</td>
<td>All Prof. Amit Singal</td>
</tr>
</tbody>
</table>

---

**SATURDAY, 9 SEPTEMBER 2023, 08.30-09.30 CEST**

**Title:** Bridging the Gap: Integrating Specialties for Optimal Focal Liver Lesions Diagnosis and Management

<table>
<thead>
<tr>
<th>TIME (CEST)</th>
<th>TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:40</td>
<td>Check points inhibitors in HCC: State of the Art.</td>
<td>Prof. Tim Meyer</td>
</tr>
<tr>
<td>08:40-09:00</td>
<td>Immunologic effects of minimally invasive tumor therapies - the ImmuMITT study.</td>
<td>Dr. Lynn Jeanette Savic</td>
</tr>
<tr>
<td>09:00-09:20</td>
<td>Today INSPIRE, tomorrow immunotherapies combos.</td>
<td>Prof. Maxime Ronot</td>
</tr>
<tr>
<td>09:20-09:30</td>
<td>Tumor board discussion</td>
<td>All faculty</td>
</tr>
</tbody>
</table>
ILCA 2023 Conference APP

ATTENDEES
Target people you want to meet.

SPONSORS & SUPPORTERS
Bookmark companies and meet them at the conference venue.

PROGRAMME
Create your own schedule of sessions you want to attend.
Join the ILCA community becoming an ILCA Member

The ILCA community currently counts around 300 eminent members from 30 countries, as well as numerous supporters who contribute to and participate in the ILCA events (Single Topic Workshops, Webinars and Annual Conferences) and other ILCA initiatives.

Contact Us

International Liver Cancer Association (ILCA)
Avenue des arts, 47
B-1000 Brussels – Belgium

Tel: +32 (0)2 320 2531
Email: info@ilca-online.org
Website: www.ilca-online.org